Scientific communications organisation the Envision Pharma Group has revamped its top team, promoting David Thompson to chief executive officer as Brian Hepburn shifts to become its executi
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio